

- **Name:** Minsuk Kwon
 - **Current Position & Affiliation:** Clinical assistant professor, Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
 - **Country:** Korea
-
- **Educational Background:**
 - 2004.3. – 2010.2. M.D., College of Medicine, Chung-Ang University, Seoul, Korea
 - 2012.3. – 2014.2. M.S. Internal Medicine, College of Medicine, Chung-Ang University, Seoul, Korea
 - 2015.3. – 2019.2. Ph.D. Immunology, Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea
 - **Professional Experience:**
 - 2011.3. – 2015.2. Residency, Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea
 - 2019.3. – 2021.2. Clinical fellow, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Seoul, Korea
 - 2021.3. – 2022.2 Clinical assistant professor, Department of Hematology-Oncology, Ajou University School of Medicine, Gyeonggi-do, Korea
 - 2022.3. – 2024.4 Assistant professor, Department of Hematology-Oncology, Ajou University School of Medicine, Gyeonggi-do, Korea
 - 2024.5 – present Clinical assistant professor, Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
 - **Professional Organizations:**
 - Korean Society of Medical Oncology
 - Korean Cancer Study Group
 - Korean Association of Immunologists
 - American Society of Clinical Oncology
 - European Society of Medical Oncology
 - **Main Scientific Publications:**

1. **Kwon, M**, Kim G, Kim R et al. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. *J Immunother Cancer*. 2022;10:e005041. doi: 10.1136/jitc-2022-005041
2. Kim, R., **Kwon, M.**, An, M., Kim, S.T., Smith, S.A., et.al. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD1 therapy. *Annals of Oncology*. (2021). doi:10.1016/j.annonc.2021.10.009
3. **Kwon M**, An M, Klempner SJ, Lee H, Kim KM, et al. Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer. *Cancer Discov*. 2021;11(9) 2168-2185.
4. **Kwon M**, Kim CG, Lee H, Cho H, et al. PD-1 blockade reinvigorates bone marrow CD8⁺ T cells from patients with multiple myeloma in the presence of TGF- β inhibitors. *Clinical Cancer Res*. 2020;26;1644-55
5. **Kwon M**, Ku BM, Olsen S, et al. Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors. *Cancer Med*. 2022 Apr 19. doi: 10.1002/cam4.4663.